PMID- 12204953
OWN - NLM
STAT- MEDLINE
DCOM- 20030211
LR  - 20231105
IS  - 1071-412X (Print)
IS  - 1098-6588 (Electronic)
IS  - 1071-412X (Linking)
VI  - 9
IP  - 5
DP  - 2002 Sep
TI  - Calcium phosphate nanoparticles induce mucosal immunity and protection against 
      herpes simplex virus type 2.
PG  - 1021-4
AB  - Previously we reported that calcium phosphate nanoparticles (CAP) represented a 
      superior alternative to alum adjuvants in mice immunized with viral protein. 
      Additionally, we showed that CAP was safe and elicited no detectable 
      immunoglobulin E (IgE) response. In this study, we demonstrated that following 
      mucosal delivery of herpes simplex virus type 2 (HSV-2) antigen with CAP, CAP 
      adjuvant enhanced protective systemic and mucosal immunity versus live virus. 
      Mice were immunized intravaginally and intranasally with HSV-2 protein plus CAP 
      adjuvant (HSV-2+CAP), CAP alone, phosphate-buffered saline, or HSV-2 alone. 
      HSV-2+CAP induced HSV-specific mucosal IgA and IgG and concurrently enhanced 
      systemic IgG responses. Our results demonstrate the potency of CAP as a mucosal 
      adjuvant. Furthermore, we show that systemic immunity could be induced via the 
      mucosal route following inoculation with CAP-based vaccine. Moreover, 
      neutralizing antibodies were found in the sera of mice immunized intranasally or 
      intravaginally with HSV-2+CAP. Also, the results of our in vivo experiments 
      indicated that mice vaccinated with HSV-2+CAP were protected against live HSV-2 
      infection. In conclusion, these preclinical data support the hypothesis that CAP 
      may be an effective mucosal adjuvant that protects against viral infection.
FAU - He, Qing
AU  - He Q
AD  - BioSante Pharmaceuticals, Inc., Smyrna, Georgia 30082, USA. qinghe@bellsouth.net
FAU - Mitchell, Alaina
AU  - Mitchell A
FAU - Morcol, Tulin
AU  - Morcol T
FAU - Bell, Steve J D
AU  - Bell SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Diagn Lab Immunol
JT  - Clinical and diagnostic laboratory immunology
JID - 9421292
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Calcium Phosphates)
RN  - 0 (alpha-tricalcium phosphate)
RN  - 0 (tetracalcium phosphate)
RN  - 701EKV9RMN (calcium phosphate, monobasic, anhydrous)
RN  - 97Z1WI3NDX (calcium phosphate)
RN  - L11K75P92J (calcium phosphate, dibasic, anhydrous)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Animals
MH  - Calcium Phosphates/*pharmacology
MH  - Female
MH  - Herpes Genitalis/immunology/mortality/*prevention & control
MH  - Herpesvirus 2, Human/*immunology
MH  - *Immunization
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nasal Mucosa
MH  - Particle Size
MH  - Vagina
PMC - PMC120054
EDAT- 2002/09/03 10:00
MHDA- 2003/02/13 04:00
PMCR- 2002/09/01
CRDT- 2002/09/03 10:00
PHST- 2002/09/03 10:00 [pubmed]
PHST- 2003/02/13 04:00 [medline]
PHST- 2002/09/03 10:00 [entrez]
PHST- 2002/09/01 00:00 [pmc-release]
AID - 0022 [pii]
AID - 10.1128/cdli.9.5.1021-1024.2002 [doi]
PST - ppublish
SO  - Clin Diagn Lab Immunol. 2002 Sep;9(5):1021-4. doi: 
      10.1128/cdli.9.5.1021-1024.2002.